Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Ardelyx Inc

ARDX
Current price
6.48 USD +0.09 USD (+1.41%)
Last closed 6.44 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 642 763 136 USD
Yield for 12 month +35.56 %
1Y
3Y
5Y
10Y
15Y
ARDX
21.11.2021 - 28.11.2021

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Address: 400 Fifth Avenue, Waltham, MA, United States, 02451

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.55 USD

P/E ratio

Dividend Yield

Current Year

+124 456 000 USD

Last Year

+52 158 000 USD

Current Quarter

+34 363 000 USD

Last Quarter

+56 391 000 USD

Current Year

+106 661 000 USD

Last Year

+48 041 000 USD

Current Quarter

+29 286 000 USD

Last Quarter

+49 343 000 USD

Key Figures ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -61 984 000 USD
Operating Margin TTM -81.44 %
PE Ratio
Return On Assets TTM -16.22 %
PEG Ratio -0.08
Return On Equity TTM -49.84 %
Wall Street Target Price 13.55 USD
Revenue TTM 124 456 000 USD
Book Value 0.72 USD
Revenue Per Share TTM 0.57 USD
Dividend Share
Quarterly Revenue Growth YOY -22.2 %
Dividend Yield
Gross Profit TTM 15 540 000 USD
Earnings Share -0.3 USD
Diluted Eps TTM -0.3 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -53.09 %

Dividend Analytics ARDX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 12.1685
Price Sales TTM 13.1996
Enterprise Value EBITDA -27.3593
Price Book MRQ 9.8478

Financials ARDX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARDX

For 52 weeks

3.16 USD 10.13 USD
50 Day MA 8.43 USD
Shares Short Prior Month 36 305 566
200 Day MA 5.67 USD
Short Ratio 6.33
Shares Short 35 017 704
Short Percent 15.3 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics